J. Gary Booker, Md, Apmc

Shreveport, Louisiana 71104-2136

0 studies enrolling now · 14 studies all time

What they study most

Alzheimer's Disease, Bipolar Disorder, Depression, Depressive Disorder, Major, Generalized Anxiety Disorder, Schizophrenia, Schizophrenia and Predominant Negative Symptoms

Studies at this site

Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms — Completed
Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder — Completed
A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder — Completed
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02) — Completed
Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder — Completed
Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients — Completed
Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder — Completed
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Stopped early
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) — Completed
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 — Completed
Effects of ONO-2506PO in Patients With Alzheimer's Disease — Completed
Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease — Stopped early